Brought to you by 
Roche licenses synthetic erythropoeisis protein from Gryphon
17 Jun 2014
Executive Summary
Roche licensed exclusive worldwide development, manufacturing, and marketing rights to Gryphon Sciences' (developing synthetic protein therapeutics) erythropoiesis protein, an anemia treatment that has finished preclinical development.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche licenses synthetic erythropoeisis protein from Gryphon
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice